市場調查報告書
商品編碼
1466242
皮質類固醇抑制劑市場:按藥物、治療類型、分銷管道和最終用戶分類 - 全球預測 2024-2030Adrenal Corticosteroid Inhibitors Market by Drug (Aminoglutethimide, Levoketoconazole, Metyrapone), Treatment Type (Breast Cancer, Cushing's Syndrome, Prostate Cancer), Distribution Channel, End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年皮質類固醇抑制劑市場規模為24.9億美元,預計2024年將達28億美元,2030年將達57.8億美元,複合年成長率為12.75%。
皮質類固醇抑制劑是一組藥物化合物,旨在抑制體內皮質醇和其他腎上腺皮質荷爾蒙的產生和抑製作用。腎上腺皮質荷爾蒙是一組主要由位於腎臟上方的腎上腺所產生的荷爾蒙。這些荷爾蒙調節許多生理過程,包括免疫反應、發炎、壓力、新陳代謝和血壓。肥胖、第2型糖尿病和卵巢症候群等內分泌疾病的流行導致對基於腎上腺皮質荷爾蒙抑制劑的治療的需求不斷成長。然而,醫藥品認證過程中的監管障礙可能會對尋求核准新藥或擴大適應症的製藥公司造成嚴重的時間延誤和財務成本。此外,隨著療效、特異性和副作用改善的新藥的持續開發,預計將加速全球最終用途部門對皮質類固醇抑制劑的使用。
主要市場統計 | |
---|---|
基準年[2023] | 24.9億美元 |
預測年份 [2024] | 28億美元 |
預測年份 [2030] | 57.8億美元 |
複合年成長率(%) | 12.75% |
奧西洛司他藥物製劑的使用正在迅速增加。
胺基是一種老一代腎上腺類固醇抑制劑,可阻止腎上腺皮質中膽固醇轉化為孕烯醇酮並抑制皮質醇的產生。Ketoconazole是一種新型臨床實驗藥物,透過抑制多種參與類固醇生成的酵素來抑制皮質醇合成,可有效治療內源性庫欣氏症候群。 Metyrapone 是一種皮質類固醇抑制劑,可抑制 11B-氧化酵素(產生皮質醇的酵素)。該藥物用作庫欣氏症候群急性發作患者的短期治療選擇,或用作確定皮質醇反應性的診斷工具。 Osilodrostat 是一種有效的口服 11B-羥化酶抑制劑,已被證明可以快速、持續地降低庫欣氏症患者的平均尿液遊離皮質醇。
治療類型 增加皮質類固醇抑制劑在庫欣氏症候群治療的使用
皮質類固醇抑制劑用於治療荷爾蒙受體陽性(HR+)轉移性乳癌。當Aromatase抑制劑(HR+乳癌的第一線藥物)產生抗藥性時,就會需要這些抑制劑。皮質類固醇抑制劑在庫欣氏症候群的治療中發揮重要作用,庫欣氏症候群是一種由長期暴露於高濃度皮質醇所引起的荷爾蒙失調。這些抑制劑旨在抑制皮質醇的產生並緩解與皮質醇過多相關的症狀,例如肥胖、疲勞和高血壓。儘管進行了初始荷爾蒙療法,但晚期前列腺癌常常由於雄性激素的持續產生而進展。皮質類固醇抑制劑,例如醋酸Abiraterone,與皮質類固醇藥物潑尼鬆一起使用,以抑制雄激素的產生和癌症的生長。
銷售管道:不斷發展的皮質類固醇抑制劑線上分銷管道
醫院藥局為醫院和診所收治的患者提供服務,在皮質類固醇抑制劑的分銷中發揮重要作用。這些設施通常設有現場藥房,以確保藥物(包括皮質類固醇抑制劑)的可及性和可用性。醫院藥局主要直接向製造商和供應商購買藥品。近年來,由於人們對宅配服務的日益偏好以及網際網路在全球範圍內的普及,在線藥房迅速普及。網上藥局提供送貨上門的便利,同時透過直接從製造商和授權經銷商處採購來維持品質保證。但是,請警惕一些不受監管的電子商務網站上銷售的假藥。零售藥局仍然是皮質類固醇抑制劑分銷管道的重要組成部分,因為它們廣泛存在於世界各地的住宅。零售藥局可以快速為需要非成藥藥和處方箋藥的顧客提供服務。
最終用戶:專門中心大量採用皮質類固醇抑制劑
使用皮質類固醇抑制劑的主要場所是醫院,在那裡可以提供需要緊急干預的先進診斷工具和綜合治療。患有嚴重或危及生命的疾病(例如腎上腺腺癌或需要手術的患者)的患者通常在醫院接受抑制劑治療。專科中心專注於為患有特定疾病的患者提供專門護理。當涉及皮質類固醇抑制劑時,這些中心治療罕見內分泌疾病的患者,專業知識和經驗對於處理這些複雜的病例至關重要。
區域洞察
在美洲,我們看到人們對愛迪生氏症、庫欣氏症候群和其他腎上腺皮質疾病的認知不斷提高,大型製藥企業的研究經費不斷增加,大型製藥企業在歐盟國家,由於人們對腎上腺疾病的早期檢測和有效治療方法的認知不斷提高,對皮質類固醇抑制劑的需求正在增加。隨著政府投資改善醫療基礎設施、提高公眾健康意識和促進臨床研究活動,歐洲、中東和非洲地區為腎上腺皮質荷爾蒙抑制劑製造商提供了巨大的機會。隨著製藥公司透過強力的研發策略開發新型抑制劑以及政府政策鼓勵對生物製藥製造廠的投資,皮質類固醇抑制劑在亞太地區不斷成長。此外,線上藥局和分銷平台的出現預計將擴大分銷並改善腎上腺皮質疾病的治療效果。
FPNV定位矩陣
FPNV定位矩陣對於評估皮質類固醇抑制劑市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對皮質類固醇抑制劑市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.皮質類固醇抑制劑市場規模及預測是多少?
2.在皮質類固醇抑制劑市場的預測期內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.皮質類固醇抑制劑市場的技術趨勢和法規結構是什麼?
4.皮質類固醇抑制劑市場主要供應商的市場佔有率為何?
5. 進入皮質類固醇抑制劑市場合適的型態和策略手段是什麼?
[184 Pages Report] The Adrenal Corticosteroid Inhibitors Market size was estimated at USD 2.49 billion in 2023 and expected to reach USD 2.80 billion in 2024, at a CAGR 12.75% to reach USD 5.78 billion by 2030.
Adrenal corticosteroid inhibitors are a class of pharmaceutical compounds designed to suppress the production or inhibitory action of cortisol and other corticosteroids within the body. Corticosteroids are a group of hormones that are primarily produced by the adrenal glands that are located above each kidney. These hormones regulate numerous physiological processes such as immune response, inflammation, stress, metabolism, and blood pressure. Prevalence of endocrine diseases, including obesity, type 2 diabetes mellitus, and polycystic ovary syndrome, have contributed to a higher need for Adrenal corticosteroid inhibitor-based therapies. However, regulatory hurdles pertaining to drug approval processes can impose significant time delays and financial costs on pharmaceutical companies seeking approval for new drugs or expanded indications. Furthermore, the ongoing development of new drugs with improved efficacy, specificity, and reduced side effects is anticipated to accelerate the use of adrenal corticosteroid inhibitors by the end-use sectors globally.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.49 billion |
Estimated Year [2024] | USD 2.80 billion |
Forecast Year [2030] | USD 5.78 billion |
CAGR (%) | 12.75% |
Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
Aminoglutethimide is an older-generation adrenal steroid inhibitor that stops the conversion of cholesterol to pregnenolone in the adrenal cortex, thereby reducing cortisol production. Levoketoconazole is a novel investigational drug and shows results in treating endogenous Cushing's syndrome by inhibiting cortisol synthesis by blocking multiple enzymes involved in steroidogenesis. Metyrapone is an adrenal corticosteroid inhibitor that inhibits 11B-hydroxylase, an enzyme in cortisol production. This drug is used as a short-term treatment option for patients experiencing acute episodes of Cushing's syndrome or as a diagnostic tool to determine cortisol responsiveness. Osilodrostat is a potent oral inhibitor of 11B-hydroxylase that has demonstrated rapid and sustained reductions in mean urinary-free cortisol levels in patients with Cushing's disease.
Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome
Adrenal corticosteroid inhibitors are utilized in the treatment of hormone-receptor-positive (HR+) metastatic breast cancer. The need for these inhibitors arises when patients become resistant to aromatase inhibitors, which are the first line of treatment for HR+ breast cancer. Adrenal corticosteroid inhibitors play a critical role in managing Cushing's syndrome, a hormonal disorder caused by prolonged exposure to high levels of cortisol. These inhibitors aim to reduce cortisol production and alleviate symptoms associated with cortisol excess, such as obesity, fatigue, and hypertension. Advanced prostate cancer often progresses despite initial hormone therapy due to the continued production of androgen hormones. Adrenal corticosteroid inhibitors, such as abiraterone acetate, are combined with prednisone, a corticosteroid drug, to suppress androgen production and limit cancer growth.
Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
In the distribution of adrenal corticosteroid inhibitors, hospital pharmacies play a crucial role, as they cater to patients admitted in hospitals and clinics. These medical facilities usually have an in-house pharmacy, ensuring the accessibility and availability of medications, including adrenal corticosteroid inhibitors. Hospital pharmacies mainly procure drugs directly from manufacturers or suppliers. With the growing preference for home delivery services, online pharmacies have rapidly gained popularity in recent years due to increasing internet penetration worldwide. Online pharmacies offer convenience through door-to-door deliveries while maintaining quality assurance by sourcing directly from manufacturers or authorized distributors. However, there is a need to be cautious regarding counterfeit drugs sold on some unregulated e-commerce websites. Retail pharmacies remain an integral part of the distribution channel landscape for adrenal corticosteroid inhibitors due to their widespread presence across residential areas worldwide. They serve walk-in customers who require over-the-counter or prescription-based medications promptly.
End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
Hospitals remain a primary setting for administering adrenal corticosteroid inhibitors owing to their ability to provide comprehensive care with access to advanced diagnostic tools and emergency intervention if required. Patients with severe or life-threatening conditions, such as adrenal carcinoma or those requiring surgery, often receive their inhibitor treatments in a hospital setting. Specialty centers focus on providing specialized care to patients with specific medical conditions. In the context of adrenal corticosteroid inhibitors, these centers cater to patients with rare endocrine disorders where expert knowledge and experience are vital in managing these complex cases.
Regional Insights
The adrenal corticosteroid inhibitors market is evolving in the Americas owing to the growing awareness of Addison's disease, Cushing's syndrome, and other adrenocortical disorders, increased research funding from the and collaboration with major pharmaceutical companies facilitating advanced clinical trials and novel drug development. In EU countries, the demand for adrenal corticosteroid inhibitors has escalated due to increased awareness about early detection and effective treatment options for adrenal diseases. The EMEA region represents a significant opportunity for adrenal corticosteroid inhibitor manufacturers as governments invest in improving healthcare infrastructure, raising public health awareness, and promoting clinical research activities. Adrenal corticosteroid inhibitors are growing in the APAC region, with pharmaceutical companies developing novel inhibitors through robust R&D strategies and government policies encouraging investment in biopharmaceutical manufacturing plants. Furthermore, the emergence of online pharmacy and distribution platforms is anticipated to expand the distribution and improve the treatment outcomes of adrenocortical medical conditions.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Adrenal Corticosteroid Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Adrenal Corticosteroid Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Adrenal Corticosteroid Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adooq Bioscience LLC, Cayman Chemical Company, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Enzo Life Sciences, Inc., Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., HRA Pharma Rare Diseases SAS by Perrigo Company plc, MedChemExpress, Merck KGaA, Novartis AG, Orphagen Pharmaceuticals, Pfizer Inc., Sparrow Pharmaceuticals Inc., Steris Healthcare PVT Ltd, Tocris Bioscience by Bio-Techne Corporation, and Xeris Biopharma Holdings, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Adrenal Corticosteroid Inhibitors Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Adrenal Corticosteroid Inhibitors Market?
3. What are the technology trends and regulatory frameworks in the Adrenal Corticosteroid Inhibitors Market?
4. What is the market share of the leading vendors in the Adrenal Corticosteroid Inhibitors Market?
5. Which modes and strategic moves are suitable for entering the Adrenal Corticosteroid Inhibitors Market?